Amylyx Pharmaceuticals (AMLX) Operating Margin (2021 - 2024)
Historic Operating Margin for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q4 2024 value amounting to 155.0%.
- Amylyx Pharmaceuticals' Operating Margin fell 1565200.0% to 155.0% in Q4 2024 from the same period last year, while for Sep 2025 it was 599.87%, marking a year-over-year decrease of 4742800.0%. This contributed to the annual value of 275.44% for FY2024, which is 2844300.0% down from last year.
- Latest data reveals that Amylyx Pharmaceuticals reported Operating Margin of 155.0% as of Q4 2024, which was down 1565200.0% from 18187.74% recorded in Q3 2024.
- Amylyx Pharmaceuticals' 5-year Operating Margin high stood at 18.63% for Q2 2023, and its period low was 18187.74% during Q3 2024.
- In the last 4 years, Amylyx Pharmaceuticals' Operating Margin had a median value of 155.0% in 2024 and averaged 4009.91%.
- Its Operating Margin has fluctuated over the past 5 years, first soared by 100132600bps in 2023, then plummeted by -182044700bps in 2024.
- Over the past 4 years, Amylyx Pharmaceuticals' Operating Margin (Quarter) stood at 8041.4% in 2021, then surged by 98bps to 167.91% in 2022, then surged by 101bps to 1.53% in 2023, then crashed by -10247bps to 155.0% in 2024.
- Its last three reported values are 155.0% in Q4 2024, 18187.74% for Q3 2024, and 7457.09% during Q2 2024.